CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 126 enrolled
Drug / intervention
Bevacizumabdrug
Likely dose
Bevacizumab 1.25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00745498
NCT00745498N/ACompleted
CompareCT.gov

Efficacy Study of Pre- and Intra-operative Intravitreal Bevacizumab Injection on Postoperative Vitreous Hemorrhage After Diabetic Vitrectomy

Seoul National University Bundang Hospital·interventional·Posted Sep 3, 2008·Updated Dec 21, 2015

In Brief

A clinical study evaluating Bevacizumab for Proliferative Diabetic Retinopathy and Vitreous Hemorrhage. Completed, enrolled 126 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the effect of pre- and intra-operative bevacizumab injection on postoperative vitreous hemorrhage after diabetic vitrectomy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProliferative Diabetic Retinopathy, Vitreous Hemorrhage
CountriesSouth Korea
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 3, 2008
Enrollment StartJun 1, 2008
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 17.8 years ago

Interventions

Bevacizumabdrug

Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml)